Nurse Anesthetist - CR in Sedalia, MO Accepting Medicare
6 Nurse Anesthetist - CR nurses found. Showing 1 - 6
 Jeffrey D Terrell, CRNA Nurse Anesthetist, Certified Registered Medicare: Not Enrolled in Medicare Practice Location: 601 E 14th St, Sedalia, MO 65301 Phone: 816-461-8288 |
Chase Belnap, Nurse Anesthetist, Certified Registered Medicare: Accepting Medicare Assignments Practice Location: 601 E 14th St, Sedalia, MO 65301 Phone: 660-826-8833 |
Michael R Moulton, CRNA Nurse Anesthetist, Certified Registered Medicare: Not Enrolled in Medicare Practice Location: 601 E 14th St, Sedalia, MO 65301 Phone: 816-461-8288 |
 Connie E Kiburz, CRNA Nurse Anesthetist, Certified Registered Medicare: Not Enrolled in Medicare Practice Location: 3310 W 10th St, Sedalia, MO 65301 Phone: 660-829-4024 |
Mr. Bart Dewayne Kuhns, CRNA Nurse Anesthetist, Certified Registered Medicare: Accepting Medicare Assignments Practice Location: 601 E 14th St, Sedalia, MO 65301 Phone: 660-826-8833 |
Mr. Travis John Fitzpatrick, CRNA Nurse Anesthetist, Certified Registered Medicare: Not Enrolled in Medicare Practice Location: 32020 Hill Ln, Sedalia, MO 65301 Phone: 239-682-5411 |
News Archive
New report shows the financial and social value of investing in medical research
A study commissioned by three leading scientific institutions has demonstrated substantial financial and social benefits from investment in medical research.
OraSure registers $3.5 million net loss for full year 2010
OraSure Technologies, Inc., a market leader in oral fluid diagnostics, today announced revenues of $75.0 million and $18.8 million for the year and quarter ended December 31, 2010, respectively. This compares to revenues of $77.0 million and $20.9 million for the year and quarter ended December 31, 2009.
Vtesse receives FDA's Breakthrough Therapy designation for VTS-270
Vtesse, Inc. announced today that the U.S. Food and Drug Administration has granted its drug candidate, VTS-270 for treatment of Niemann-Pick Type C1 Disease (NPC), Breakthrough Therapy designation status. Both the FDA and the European Medicines Agency (EMA) had previously granted Orphan Drug status to VTS-270, which is currently in a pivotal Phase 2b/3 clinical trial.
FDA affirms safety of Aspartame
The Calorie Control Council has stated that a rat study conducted by Italy's Ramazzini Institute is totally contradictory to the extensive scientific research and regulatory reviews conducted on aspartame. The U.S. Food & Drug Administration (FDA) has said they are not recommending any changes in the use of aspartame.
Small peptide TAxI holds promise for carrying biologic drugs into spinal cord
A small peptide dubbed TAxI is living up to its name. Recent studies show it to be an effective vehicle for shuttling functional proteins, such as active enzymes, into the spinal cord after a muscle injection.
› Verified 8 days ago
Nurse Practitioner
Registered Nurse
Nurse Anesthetist - CR
Licensed Practical Nurse
Advanced Practice Midwife